



**JOHN WAYNE
CANCER INSTITUTE**
at Saint John's Health Center



Armando E. Giuliano, MD, is Chief of Science and Medicine at John Wayne Cancer Institute at Saint John's and has been with the Institute since its inception.



Q:

What keeps John Wayne Cancer Institute at Saint John's at the forefront of innovation in cancer prevention, diagnosis and treatment?

A:

The Institute has always attracted leading talent. Many of our research scientists and clinicians have been with the Institute since its inception and work in an environment of collaborative investigation. The Institute has earned a worldwide reputation for innovation. Lymphatic mapping and the sentinel lymph node biopsy, invented by Donald L. Morton, MD, the Institute's founder and Chief, Melanoma Program, is now the international standard of care for several types of cancer. Other innovations developed at the Institute include the use of the technologically advanced PET Probe to detect tiny hidden cancers and advances in immunological research and molecular genetics that have applications for both improved diagnosis and treatment.

Q:

How long has John Wayne Cancer Institute been affiliated with Saint John's Health Center?

A:

John Wayne Cancer Institute has been affiliated with Saint John's Health Center since 1991, after relocating from UCLA. In 2007, a new permanent alliance was formed with Saint John's. This has provided stability and resources to recruit renowned scientists, research a broader spectrum of cancers and, with the opening of the Howard Keck Center, expand into new, larger and more patient-focused quarters.

Q:

Which recent developments at the Institute are you most excited about?

A:

Of course, I'm delighted with the opening of the John Wayne Cancer Centers in the new Howard Keck Center. The generous donation from the Margie and Robert E. Petersen Foundation has enabled the development of a state-of-the-art breast cancer diagnostic and treatment center within the John Wayne Cancer Centers. The dual-designation donation also provides funding for new breast cancer research. The addition of internationally renowned neurosurgeon Amin B. Kassam, MD, to our staff and the launch of the new Neuroscience Institute are placing us at the forefront of exciting developments in brain cancer diagnosis and treatment. And I'm very excited about the recent grant from Abraxis Bioscience, Inc., which enables significant expansion of the Molecular Oncology Department's biomarker research.